Symbols / ICCM
ICCM Chart
About
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 40.07M |
| Enterprise Value | 30.36M | Income | -15.29M | Sales | 2.98M |
| Book/sh | 0.14 | Cash/sh | 0.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 64 | IPO | — |
| P/E | — | Forward P/E | -9.69 | PEG | — |
| P/S | 13.47 | P/B | 4.30 | P/C | — |
| EV/EBITDA | -2.01 | EV/Sales | 10.20 | Quick Ratio | 1.76 |
| Current Ratio | 2.38 | Debt/Eq | 3.10 | LT Debt/Eq | — |
| EPS (ttm) | -0.25 | EPS next Y | -0.06 | EPS Growth | — |
| Revenue Growth | 28.40% | Earnings | 2026-03-26 | ROA | -63.43% |
| ROE | -157.91% | ROIC | — | Gross Margin | 35.06% |
| Oper. Margin | -4.51% | Profit Margin | 0.00% | Shs Outstand | 68.96M |
| Shs Float | 41.09M | Short Float | 3.86% | Short Ratio | 1.83 |
| Short Interest | — | 52W High | 1.53 | 52W Low | 0.54 |
| Beta | 2.21 | Avg Volume | 291.79K | Volume | 93.92K |
| Target Price | $3.12 | Recom | Strong_buy | Prev Close | $0.57 |
| Price | $0.58 | Change | 1.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.13
Mean price target
2. Current target
$0.58
Latest analyst target
3. DCF / Fair value
$-2.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.58
Low
$3.00
High
$3.25
Mean
$3.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-07 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-08-15 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-21 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-07-02 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-03-20 | main | Alliance Global Partners | Buy → Buy | $3 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- A freezing treatment for kidney tumors just finished 5 years of testing - Stock Titan Mon, 23 Feb 2026 13
- When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - Yahoo Finance hu, 15 Jan 2026 08
- IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales - PR Newswire Mon, 12 Jan 2026 08
- ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment - Zacks Investment Research Mon, 06 Oct 2025 07
- Investors push IceCure Medical (NASDAQ:ICCM) 13% lower this week, company's increasing losses might be to blame - simplywall.st Mon, 13 Oct 2025 07
- First Alabama breast tumor-freezing option funded by local foundation - Stock Titan hu, 19 Feb 2026 13
- IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright - Investing.com ue, 07 Oct 2025 07
- Icecure Medical stock surges after FDA approves breast cancer treatment - Investing.com Fri, 03 Oct 2025 07
- IceCure CFO who helped Nasdaq listing is stepping down - Stock Titan Mon, 09 Feb 2026 08
- Icecure Medical Ltd (ICCM) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance ue, 18 Nov 2025 08
- IceCure Medical (NASDAQ: ICCM) gets Nasdaq bid-price notice; 180 days to regain $1.00 - Stock Titan Fri, 14 Nov 2025 08
- When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - Yahoo Finance Fri, 08 Aug 2025 07
- New freezing treatment for low‑risk breast cancer reaches Missouri women - Stock Titan Wed, 11 Feb 2026 08
- IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates - Yahoo Finance Wed, 13 Aug 2025 07
- IceCure (NASDAQ: ICCM) Receives FDA Authorization for ProSense in 200,000 Patients - Stock Titan Wed, 19 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.36M | -15.25M | -16.49M | -9.60M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.32M | -14.65M | -16.98M | -9.89M |
| ReconciledDepreciation | 332.00K | 323.00K | 248.00K | 127.00K |
| ReconciledCostOfRevenue | 1.84M | 1.93M | 1.64M | 1.94M |
| EBITDA | -15.36M | -15.25M | -16.49M | -9.60M |
| EBIT | -15.70M | -15.58M | -16.74M | -9.72M |
| NetInterestIncome | 378.00K | 924.00K | -239.00K | -171.00K |
| NormalizedIncome | -15.32M | -14.65M | -16.98M | -9.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.32M | -14.65M | -16.98M | -9.89M |
| TotalExpenses | 18.99M | 18.80M | 19.82M | 13.86M |
| TotalOperatingIncomeAsReported | -15.70M | -15.58M | -16.74M | -9.72M |
| DilutedAverageShares | 51.85M | 46.51M | 37.73M | 29.10M |
| BasicAverageShares | 51.85M | 46.51M | 37.73M | 29.10M |
| DilutedEPS | -0.29 | -0.31 | -0.45 | -0.34 |
| BasicEPS | -0.29 | -0.31 | -0.45 | -0.34 |
| DilutedNIAvailtoComStockholders | -15.32M | -14.65M | -16.98M | -9.89M |
| NetIncomeCommonStockholders | -15.32M | -14.65M | -16.98M | -9.89M |
| NetIncome | -15.32M | -14.65M | -16.98M | -9.89M |
| NetIncomeIncludingNoncontrollingInterests | -15.32M | -14.65M | -16.98M | -9.89M |
| NetIncomeContinuousOperations | -15.32M | -14.65M | -16.98M | -9.89M |
| PretaxIncome | -15.32M | -14.65M | -16.98M | -9.89M |
| NetNonOperatingInterestIncomeExpense | 378.00K | 924.00K | -239.00K | -171.00K |
| TotalOtherFinanceCost | -378.00K | -924.00K | 239.00K | 171.00K |
| OperatingIncome | -15.70M | -15.58M | -16.74M | -9.72M |
| OperatingExpense | 17.15M | 16.88M | 18.18M | 11.92M |
| ResearchAndDevelopment | 7.10M | 8.27M | 9.12M | 5.88M |
| SellingGeneralAndAdministration | 10.05M | 8.60M | 9.06M | 6.04M |
| SellingAndMarketingExpense | 1.14M | 1.21M | 1.04M | 666.00K |
| GeneralAndAdministrativeExpense | 8.91M | 7.39M | 8.02M | 5.38M |
| OtherGandA | 4.65M | 3.27M | 4.16M | 2.94M |
| SalariesAndWages | 4.26M | 4.12M | 3.86M | 2.44M |
| GrossProfit | 1.45M | 1.30M | 1.45M | 2.19M |
| CostOfRevenue | 1.84M | 1.93M | 1.64M | 1.94M |
| TotalRevenue | 3.29M | 3.23M | 3.08M | 4.14M |
| OperatingRevenue | 3.29M | 3.23M | 3.08M | 4.14M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 57.65M | 46.61M | 46.50M | 36.47M |
| ShareIssued | 57.65M | 46.61M | 46.50M | 36.47M |
| TotalDebt | 459.00K | 599.00K | 597.00K | 909.00K |
| TangibleBookValue | 6.90M | 12.16M | 25.42M | 26.96M |
| InvestedCapital | 6.90M | 12.16M | 25.42M | 26.96M |
| WorkingCapital | 5.24M | 10.31M | 23.79M | 26.30M |
| NetTangibleAssets | 6.90M | 12.16M | 25.42M | 26.96M |
| CapitalLeaseObligations | 459.00K | 599.00K | 597.00K | 909.00K |
| CommonStockEquity | 6.90M | 12.16M | 25.42M | 26.96M |
| TotalCapitalization | 6.90M | 12.16M | 25.42M | 26.96M |
| TotalEquityGrossMinorityInterest | 6.90M | 12.16M | 25.42M | 26.96M |
| StockholdersEquity | 6.90M | 12.16M | 25.42M | 26.96M |
| TreasuryStock | 0.00 | |||
| RetainedEarnings | -105.38M | -90.06M | -75.41M | -58.43M |
| AdditionalPaidInCapital | 112.28M | 102.22M | 100.83M | 85.39M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 5.67M | 4.25M | 4.77M | 5.32M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 161.00K | 376.00K | 430.00K | 1.30M |
| OtherNonCurrentLiabilities | 618.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 161.00K | 376.00K | 430.00K | 685.00K |
| LongTermCapitalLeaseObligation | 161.00K | 376.00K | 430.00K | 685.00K |
| CurrentLiabilities | 5.51M | 3.87M | 4.34M | 4.02M |
| CurrentDeferredLiabilities | 334.00K | 187.00K | 646.00K | 884.00K |
| CurrentDeferredRevenue | 334.00K | 187.00K | 646.00K | 884.00K |
| CurrentDebtAndCapitalLeaseObligation | 298.00K | 223.00K | 167.00K | 224.00K |
| CurrentCapitalLeaseObligation | 298.00K | 223.00K | 167.00K | 224.00K |
| CurrentProvisions | 766.00K | 677.00K | 601.00K | 472.00K |
| PayablesAndAccruedExpenses | 4.12M | 2.78M | 2.92M | 2.44M |
| CurrentAccruedExpenses | 2.88M | 2.28M | 2.21M | 1.56M |
| Payables | 1.23M | 502.00K | 714.00K | 881.00K |
| AccountsPayable | 1.23M | 502.00K | 714.00K | 881.00K |
| TotalAssets | 12.58M | 16.41M | 30.19M | 32.28M |
| TotalNonCurrentAssets | 1.82M | 2.23M | 2.06M | 1.96M |
| OtherNonCurrentAssets | 46.00K | 34.00K | 34.00K | 333.00K |
| NonCurrentPrepaidAssets | 333.00K | |||
| NetPPE | 1.78M | 2.19M | 2.02M | 1.63M |
| AccumulatedDepreciation | -1.55M | -1.22M | -906.00K | -298.00K |
| GrossPPE | 3.33M | 3.41M | 2.93M | 1.92M |
| Leases | 212.00K | 209.00K | 207.00K | 133.00K |
| OtherProperties | 2.54M | 2.64M | 2.19M | 1.48M |
| MachineryFurnitureEquipment | 575.00K | 558.00K | 531.00K | 311.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 10.75M | 14.18M | 28.13M | 30.32M |
| RestrictedCash | 0.00 | 296.00K | 0.00 | |
| PrepaidAssets | 793.00K | 619.00K | 952.00K | 1.98M |
| Inventory | 1.99M | 2.27M | 2.86M | 1.96M |
| FinishedGoods | 349.00K | 568.00K | 935.00K | 794.00K |
| WorkInProcess | 231.00K | 316.00K | 356.00K | 457.00K |
| RawMaterials | 1.41M | 1.39M | 1.57M | 704.00K |
| Receivables | 409.00K | 228.00K | 366.00K | 771.00K |
| OtherReceivables | 31.00K | 11.00K | 164.00K | 187.00K |
| TaxesReceivable | 157.00K | 114.00K | 124.00K | 128.00K |
| AccountsReceivable | 221.00K | 103.00K | 78.00K | 456.00K |
| AllowanceForDoubtfulAccountsReceivable | -3.00K | |||
| GrossAccountsReceivable | 224.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 7.56M | 11.06M | 23.66M | 25.62M |
| OtherShortTermInvestments | 0.00 | 529.00K | 0.00 | |
| CashAndCashEquivalents | 7.56M | 10.53M | 23.66M | 25.62M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.63M | -13.03M | -15.18M | -13.14M |
| IssuanceOfCapitalStock | 9.19M | 0.00 | 13.57M | 30.55M |
| CapitalExpenditure | -71.00K | -480.00K | -891.00K | -533.00K |
| EndCashPosition | 7.56M | 10.53M | 23.66M | 25.62M |
| BeginningCashPosition | 10.53M | 23.66M | 25.62M | 3.50M |
| EffectOfExchangeRateChanges | -39.00K | 25.00K | -356.00K | 43.00K |
| ChangesInCash | -2.93M | -13.15M | -1.61M | 22.08M |
| FinancingCashFlow | 9.19M | 83.00K | 13.58M | 30.89M |
| CashFlowFromContinuingFinancingActivities | 9.19M | 83.00K | 13.58M | 30.89M |
| ProceedsFromStockOptionExercised | 0.00 | 83.00K | 2.00K | 337.00K |
| NetCommonStockIssuance | 9.19M | 0.00 | 13.57M | 30.55M |
| CommonStockIssuance | 9.19M | 0.00 | 13.57M | 30.55M |
| InvestingCashFlow | 446.00K | -684.00K | -891.00K | 3.79M |
| CashFlowFromContinuingInvestingActivities | 446.00K | -684.00K | -891.00K | 3.79M |
| NetOtherInvestingChanges | -12.00K | 296.00K | -296.00K | |
| NetInvestmentPurchaseAndSale | 529.00K | -500.00K | 0.00 | 4.62M |
| SaleOfInvestment | 1.90M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -1.37M | -500.00K | 0.00 | |
| NetPPEPurchaseAndSale | -71.00K | -480.00K | -891.00K | -533.00K |
| PurchaseOfPPE | -71.00K | -480.00K | -891.00K | -533.00K |
| OperatingCashFlow | -12.56M | -12.55M | -14.29M | -12.61M |
| CashFlowFromContinuingOperatingActivities | -12.56M | -12.55M | -14.29M | -12.61M |
| ChangeInWorkingCapital | 1.51M | 523.00K | 214.00K | -3.16M |
| ChangeInOtherCurrentLiabilities | 582.00K | -500.00K | -390.00K | 496.00K |
| ChangeInOtherCurrentAssets | 271.00K | 182.00K | 245.00K | -607.00K |
| ChangeInPayablesAndAccruedExpense | 730.00K | -212.00K | -167.00K | 236.00K |
| ChangeInPayable | 730.00K | -212.00K | -167.00K | 236.00K |
| ChangeInAccountPayable | 730.00K | -212.00K | -167.00K | 236.00K |
| ChangeInPrepaidAssets | -237.00K | 496.00K | 1.05M | -2.03M |
| ChangeInInventory | 287.00K | 582.00K | -902.00K | -891.00K |
| ChangeInReceivables | -118.00K | -25.00K | 378.00K | -362.00K |
| ChangesInAccountReceivables | -118.00K | -25.00K | 378.00K | -362.00K |
| OtherNonCashItems | -29.00K | |||
| StockBasedCompensation | 869.00K | 1.31M | 1.86M | 316.00K |
| DepreciationAmortizationDepletion | 332.00K | 323.00K | 248.00K | 127.00K |
| DepreciationAndAmortization | 332.00K | 323.00K | 248.00K | 127.00K |
| Depreciation | 332.00K | 323.00K | 248.00K | 127.00K |
| OperatingGainsLosses | 39.00K | -25.00K | 359.00K | 5.00K |
| NetForeignCurrencyExchangeGainLoss | 39.00K | -25.00K | 359.00K | 5.00K |
| NetIncomeFromContinuingOperations | -15.32M | -14.65M | -16.98M | -9.89M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ICCM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|